Becton, Dickinson and Company (BDX)

Market Cap	67.55B
Revenue (ttm)	19.49B
Net Income (ttm)	1.22B
Shares Out	288.90M
EPS (ttm)	4.19
PE Ratio	55.81
Forward PE	17.33
Dividend	$3.80 (1.63%)
Ex-Dividend Date	Mar 7, 2024

Volume	771,789
Open	232.33
Previous Close	234.36
Day's Range	230.03 - 234.57
52-Week Range	229.40 - 287.32
Beta	0.46
Analysts	Buy
Price Target	287.67 (+23.03%)
Earnings Date	May 2, 2024

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascula...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 73,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX

Financial Performance

In 2023, BDX's revenue was $19.37 billion, an increase of 2.66% compared to the previous year's $18.87 billion. Earnings were $1.42 billion, a decrease of -15.69%.

Analyst Forecast

According to 6 analysts, the average rating for BDX stock is "Buy." The 12-month stock price forecast is $287.67, which is an increase of 23.03% from the latest price.

Price Target

$287.67

(23.03% upside)

Analyst Consensus: Buy